Damon Runyon News

January 6, 2016

Mark A. Lemmon, PhD (Damon Runyon Scholar ’97-‘98, Damon Runyon Fellow ’93-’96) of Yale University, New Haven, and colleagues at The Children's Hospital of Philadelphia reported that a next-generation ALK inhibitor drug, called PF-06463922, shows promise in treating pediatric neuroblastoma. In animal models, it caused rapid and sustained tumor regression and was more effective than the FDA-approved ALK inhibitor crizotinib.